证券代码：300238 证券简称：冠昊生物 公告编号：2025-053 冠昊生物科技股份有限公司 2025 年第三季度报告披露提示性公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 2025 年 10 月 28 日，冠昊生物科技股份有限公司(以下简称"公司")召开 了第六届董事会审计委员会第十四次会议和第六届董事会第十七次会议，审议通 过了公司《2025 年第三季度报告》。公司《2025 年第三季度报告》于 2025 年 10 月 29 日 在 中 国 证 监 会 指 定 的 创 业 板 信 息 披 露 网 站 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露。敬请投资者注意查阅。 特此公告。 冠昊生物科技股份有限公司董事会 2025 年 10 月 29 日 特别提示：本公司 2025 年第三季度报告于 2025 年 10 月 29 日在中国证监会 指定的创业板信息披露网站上披露，敬请投资者注意查阅。 ...

证券代码：300238 证券简称：冠昊生物 公告编号：2025-054 冠昊生物科技股份有限公司 第六届董事会第十七次会议决议公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 1、冠昊生物科技股份有限公司(以下简称"公司")第六届董事会第十七次 会议，会议通知已于 2025 年 10 月 24 日以专人送达、邮件等方式送达全体董事。 2、本次会议于 2025 年 10 月 28 日下午 14:15 在公司会议室采取现场会议和 通讯会议相结合的方式召开。 3、本次会议应出席董事 5 名，实际出席会议董事 5 名。其中，董事孙峰女 士、独立董事邓超先生以通讯方式出席会议。 4、本次会议由公司董事长张永明先生召集并主持，公司部分高级管理人员 列席了会议。 5、本次会议的召集和召开符合《公司法》《公司章程》和《董事会议事规 则》的有关规定。 （一） 审议通过《关于公司<2025 年第三季度报告>的议案》 公司《2025 年第三季度报告》详见 2025 年 10 月 29 日刊登在中国证监会指 定的创业板信息披露网站巨潮资讯网（http:/ ...

Financial Performance - The company's revenue for Q3 2025 was ¥92,610,785.08, representing a 4.72% increase year-over-year[5] - Net profit attributable to shareholders decreased by 17.87% to ¥6,314,402.45 for the quarter[5] - The net profit after deducting non-recurring gains and losses surged by 358.61% to ¥6,016,683.90[5] - Total operating revenue for the third quarter reached ¥293,480,433.06, an increase of 5.8% compared to ¥278,135,520.40 in the previous year[19] - Net profit for the period was ¥20,429,167.53, slightly down from ¥20,658,923.30, indicating a decrease of 1.1%[20] - The company's gross profit margin was approximately 10.9%, compared to 10.2% in the previous year, showing an improvement[19] Assets and Liabilities - Total assets increased by 2.67% to ¥774,506,933.18 compared to the end of the previous year[5] - The total assets of the company increased to ¥774,506,933.18 from ¥754,399,831.41, representing a growth of 2.1%[17] - Current liabilities decreased to ¥152,297,698.75 from ¥177,990,961.77, a reduction of 14.5%[17] - Long-term borrowings rose significantly to ¥100,950,000.00 from ¥76,000,000.00, an increase of 32.5%[17] - The total equity attributable to shareholders increased to ¥572,121,327.51 from ¥542,358,105.24, reflecting a growth of 5.5%[17] Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥52,635,840.17, up 62.75%[5] - Net cash flow from operating activities increased to CNY 52,635,840.17, compared to CNY 32,342,033.71 in the previous period, reflecting a growth of 63.5%[23] - Cash inflow from operating activities totaled CNY 337,580,752.35, up from CNY 323,070,746.17, indicating a rise of 4.7%[22] - Cash outflow from investing activities was CNY 30,788,916.93, a decrease from CNY 60,133,403.09, showing a reduction of 48.8%[23] - Net cash flow from financing activities decreased to CNY 15,179,779.24 from CNY 35,785,043.84, a decline of 57.6%[23] - The ending balance of cash and cash equivalents increased to CNY 141,434,634.79 from CNY 104,349,485.07, reflecting a growth of 35.5%[23] - The company reported a net increase in cash and cash equivalents of CNY 36,950,834.68, compared to CNY 8,241,079.60 in the previous period[23] Shareholder Information - Total number of common shareholders at the end of the reporting period is 28,315[10] - The largest shareholder, Beijing Century Tianfu Venture Capital Center, holds 13.58% of shares, totaling 36,016,266 shares[10] - The second largest shareholder, Beijing Tianyou Ruiyuan Medical Technology Co., Ltd., holds 6.44% of shares, totaling 17,084,822 shares[10] - The third largest shareholder, Tibet Jingan Enterprise Management Consulting Co., Ltd., holds 3.77% of shares, totaling 10,000,000 shares[10] - Guangdong Zhiguang Biotechnology Co., Ltd. holds 2.76% of shares, totaling 7,310,000 shares, which are pledged[10] - The company has not reported any changes in the top 10 shareholders due to securities lending activities[11] Expenses and Financial Metrics - Financial expenses surged by 319.33% to ¥2,714,845.66 due to interest expenses from project-specific loans[8] - Other income decreased by 80.64% to ¥1,723,707.23, primarily due to reduced government subsidies[8] - Research and development expenses totaled ¥26,237,061.42, a decrease of 3.1% from ¥28,093,493.13 in the prior year[20] - The basic earnings per share for Q3 2025 was ¥0.0238, a decrease of 4.80%[5] - The weighted average return on equity was 1.13%, down 0.31% from the previous year[5] Other Information - The company reported a significant increase in prepayments by 265.73% to ¥7,589,380.81, attributed to increased procurement[8] - The company has a bank loan application of RMB 10 million (¥10,000,000) with China Industrial and Commercial Bank, guaranteed by its wholly-owned subsidiaries[12] - The company did not undergo an audit for the third quarter financial report[25] - The company plans to implement new accounting standards starting from 2025[24]

Core Viewpoint - Guanhao Biological (300238) reported that as of October 20, 2025, the total number of shareholders is 28,525 [1] Summary by Relevant Categories - **Company Information** - Guanhao Biological has a total of 28,525 shareholders as of the specified date [1]

Core Viewpoint - The Ministry of Industry and Information Technology is implementing the recognition and review of "Little Giant" enterprises specializing in niche markets, in line with President Xi Jinping's directive to promote more specialized and innovative small and medium-sized enterprises [1]. Summary by Sections Recognition and Review Process - The recognition and review process for the 2025 "Little Giant" enterprises has been completed, including initial reviews and recommendations from provincial departments and expert evaluations [1]. Regional Statistics - A total of 3,482 new "Little Giant" enterprises were recognized in the seventh batch, while 3,916 enterprises passed the review for 2025 [3]. - Jiangsu Province leads with 807 new enterprises, followed by Guangdong Province with 691, and Zhejiang Province with 398 [3]. Detailed Lists of Enterprises - The article includes detailed lists of recognized enterprises, particularly from Ningbo City, which features numerous companies in various sectors such as electronics, materials, and technology [4][5][6][7].

Market Overview - The medical device sector increased by 0.72% on October 15, with TuoJing Life leading the gains [1] - The Shanghai Composite Index closed at 3912.21, up 1.22%, while the Shenzhen Component Index closed at 13118.75, up 1.73% [1] Top Performers - TuoJing Life (300642) closed at 25.85, up 10.38% with a trading volume of 294,900 shares and a transaction value of 756 million [1] - JiMin Health (603222) closed at 10.97, up 10.03% with a trading volume of 353,400 shares [1] - MaiLanDe (688273) closed at 43.90, up 9.75% with a trading volume of 47,500 shares [1] - KeFu Medical (301087) closed at 43.10, up 7.86% with a trading volume of 72,700 shares [1] - Rejing Bio (688068) closed at 170.79, up 6.96% with a trading volume of 34,700 shares [1] Underperformers - JinHao Medical (920925) closed at 34.05, down 3.81% with a trading volume of 15,400 shares [2] - DaBo Medical (002901) closed at 55.52, down 2.94% with a trading volume of 29,400 shares [2] - HuaDa ZhiZao (688114) closed at 68.57, down 2.93% with a trading volume of 52,400 shares [2] Capital Flow - The medical device sector saw a net inflow of 500 million in main funds, while retail investors experienced a net outflow of 214 million [2][3] - Major stocks like SaiNuo Medical (688108) had a net inflow of 129 million from main funds, while JiMin Health (603222) saw a net outflow of 471 million from retail investors [3]

Core Insights - The company shows signs of short-term recovery with revenue and profit growth, but faces long-term stagnation in core business growth and structural challenges [1] - The core business, particularly the hard dura mater patch segment, is under pressure from multiple factors including price system disruptions due to centralized procurement policies and competition from domestic products [1][6] - The company has not successfully developed a second growth curve, with ongoing reductions in R&D investment and low efficiency in technology transfer [1][8] Financial Performance - In the first half of 2025, the company reported revenue of 201 million yuan, a slight increase of 5.89% year-on-year, and a net profit of 20.4 million yuan, with a growth rate of only 1.27% [2] - Over the past five years, revenue has declined from 437 million yuan in 2020 to 377 million yuan in 2024, a cumulative decrease of 13.7% [2] - The first half of 2025 revenue represents only 53.3% of the total revenue for 2024, indicating potential challenges in achieving a full-year revenue of 400 million yuan [2] Core Business Challenges - The hard dura mater patch, which is the company's main product, generated 74.44 million yuan in the first half of 2025, accounting for 50.6% of the medical device segment's revenue [4] - Revenue growth for the biological dura mater patch was only 1.35%, and it experienced a decline of 14.7% in 2024 [4][6] - The average revenue growth rate for the biological dura mater patch from 2022 to 2024 was only 1.2%, significantly lower than the double-digit growth seen from 2019 to 2021 [4] Competitive Pressures - Centralized procurement policies have led to a price drop of approximately 30% for the hard dura mater patch, which has not been offset by volume increases [6] - Domestic competitors are rapidly advancing in technology, further intensifying market competition [6][10] - The company has not introduced significant upgrades to its hard dura mater patch products in over a decade, leading to stagnation in growth [7] R&D and Innovation - R&D spending has decreased from 57.9 million yuan in 2022 to 42.31 million yuan in 2024, with the proportion of R&D expenses to revenue falling from 15.4% to 9.6% [8] - The company has maintained a stable number of R&D personnel but has not achieved any capitalized R&D projects, indicating a lack of progress in converting R&D into revenue [8] - The company is exploring advanced fields like artificial liver and CAR-T but lacks synergy with its core dura mater patch business [8] Dependency on Core Product - The company is overly reliant on the hard dura mater patch, with other products in the medical device segment unable to significantly contribute to revenue [9] - Other medical device products, such as the chest repair membrane, have shown declining revenues, and the pharmaceutical and cell technology segments have also underperformed [9][10] - The hard dura mater patch holds a market share of 30%, but faces significant pricing pressure from centralized procurement [10]

Core Insights - The company shows signs of short-term recovery with revenue and profit growth, but long-term growth challenges and structural issues are becoming apparent [2][3] - The core business, particularly the dura mater patch segment, faces multiple pressures including pricing impacts from centralized procurement policies and competition from domestic products [2][9] - The company is struggling with a lack of innovation and slow product iteration, which hampers the emergence of a second growth curve [2][11] Financial Performance - In the first half of 2025, the company reported revenue of 201 million yuan, a slight increase of 5.89% year-on-year, and a net profit of 20.4 million yuan, with a growth rate of only 1.27% [3][4] - Over a five-year period, revenue has declined from 437 million yuan in 2020 to 377 million yuan in 2024, with a cumulative decrease of 13.7% [4] - The first half of 2025 revenue is only 53.3% of the total revenue for 2024, indicating potential challenges in achieving annual revenue targets [4] Business Segment Challenges - The dura mater patch business, which is the main revenue driver, generated 74.44 million yuan in the first half of 2025, accounting for 50.6% of the medical device segment's revenue [5][7] - Despite high gross margins of around 90%, the revenue growth for dura mater patches has stagnated, with a cumulative decline of 15.1% from 2022 to 2024 [8][9] - The company’s reliance on a single product line exposes it to risks, as other product lines have not been able to significantly contribute to revenue [12][13] Competitive Landscape - The dura mater patch market is highly competitive, with international giants holding 60% market share, and domestic competitors are rapidly advancing in technology [13] - The company’s market share for dura mater patches is approximately 30%, but it faces pressure from centralized procurement and declining prices [13] - The lack of significant product upgrades over the past decade has resulted in a stagnation of growth, with competitors making advancements in areas such as biodegradable materials [10][11] Research and Development Issues - The company has reduced R&D spending from 57.9 million yuan in 2022 to 42.31 million yuan in 2024, with R&D expenses as a percentage of revenue dropping from 15.4% to 9.6% [11] - The R&D team remains stable at 60-70 personnel, but the lack of capitalized projects indicates a slow transition from research to revenue-generating products [11] - The company’s focus on advanced fields like artificial liver and CAR-T lacks synergy with its core dura mater patch business, leading to a disconnect in innovation [11]

Company Overview - Crown Bio is located in Huangpu District, Guangzhou, Guangdong Province, and was established on October 22, 1999. The company was listed on July 6, 2011. Its main business involves the research, production, and sales of regenerative medical materials and regenerative medical implants, as well as research and clinical applications of cell therapy technology and immune cell storage [1][2]. Financial Performance - For the first half of 2025, Crown Bio achieved operating revenue of 201 million yuan, representing a year-on-year growth of 5.89%. The net profit attributable to the parent company was 20.40 million yuan, an increase of 1.27% year-on-year [2]. - Since its A-share listing, Crown Bio has distributed a total of 86.66 million yuan in dividends, with no dividends paid in the last three years [3]. Stock Performance - As of September 22, Crown Bio's stock price was 15.37 yuan per share, with a market capitalization of 4.075 billion yuan. The stock has increased by 27.66% year-to-date but has seen a decline of 4.36% over the last five trading days, 11.41% over the last 20 days, and 5.30% over the last 60 days [1]. - The stock experienced a net outflow of 7.55 million yuan in principal funds, with significant selling pressure observed [1]. Shareholder Information - As of September 10, the number of shareholders for Crown Bio was 28,200, a decrease of 2.37% from the previous period. The average number of circulating shares per person increased by 2.43% to 9,407 shares [2]. Business Segments - The revenue composition of Crown Bio is as follows: medical devices account for 73.28%, pharmaceuticals for 15.21%, and leasing and other services for 11.51% [1]. - The company operates within the pharmaceutical and biological industry, specifically in the medical device and consumables sector, and is involved in various concept sectors including medical consumables, small-cap stocks, medical beauty, and biomedicine [2].

Group 1: Financial Performance and Dividend Policy - The company has not distributed dividends for 7 consecutive years due to negative distributable profits, which complies with relevant regulations [3][18] - The management is focused on improving operational efficiency and resource allocation to meet future dividend conditions [7][18] - The company emphasizes the importance of shareholder returns and plans to develop a cautious dividend policy based on actual profit distribution conditions [3][18] Group 2: Core Business Areas - The company focuses on three main business segments: materials, pharmaceuticals, and cell therapy [3][11] - Key products in the materials segment include biological dura mater patches and sterile biological dressings, applicable in various medical fields [3][11] - The pharmaceutical segment features products like Bimekizumab, which treats inflammatory and autoimmune diseases [3][11] Group 3: Research and Development Progress - The company is actively advancing research in stem cell therapy and has ongoing projects in various medical fields, including liver disease and skin conditions [5][9] - The biological artificial liver project is currently in the preclinical research stage [9][18] - The company collaborates with several hospitals for clinical studies in areas such as cartilage repair and severe psoriasis treatment [5][9] Group 4: Market and Investor Relations - The company acknowledges the need for improved communication with investors regarding clinical results and project updates [6][9] - There are no current plans for share buybacks, but the company will adhere to regulations if such plans arise in the future [9][18] - The management is committed to maintaining transparency and fulfilling information disclosure obligations as required by regulations [6][9]